Svar Life Science

June 7, 2022

The development of robust cell-based assays for gene therapy: Behind the scenes at Novartis

In a recent Select Science Editorial Article, Dr. Harald Messer, Gene Therapies Senior Scientist at Novartis, talks about the key considerations and challenges associated with developing biologically relevant cell-based assays that reflect mechanisms of action (MoA) and drug potency that represent the functionality and safety of gene therapy products. 

The article also deals with the need for robust, customized assays in gene therapy, key considerations for potency testing, and much more.

June 7, 2022

The development of robust cell-based assays for gene therapy: Behind the scenes at Novartis

In a recent Select Science Editorial Article, Dr. Harald Messer, Gene Therapies Senior Scientist at Novartis, talks about the key considerations and challenges associated with developing biologically relevant cell-based assays that reflect mechanisms of action (MoA) and drug potency that represent the functionality and safety of gene therapy products. 

The article also deals with the need for robust, customized assays in gene therapy, key considerations for potency testing, and much more.

“I’m particularly excited about the growing pipeline of ocular gene therapies for inherited retinal dystrophies that use optogenetics,” says Harald Messer.

“With each project, there are new analytical methods being developed, so we can ensure the efficacy and safety of these AAV-based therapies for our patients, and Svar is an ideal partner to ensure the success of this work.”


Complete the form to get access to the article